What are the appropriate first‑line pharmacologic options and dosing for generalized anxiety disorder in an adult without contraindications?

First-Line Medication for Anxiety

Start with escitalopram 10 mg once daily or sertraline 25–50 mg once daily as your first-line pharmacologic treatment for generalized anxiety disorder, as these SSRIs demonstrate the best combination of efficacy, tolerability, and lowest discontinuation-symptom burden. 1, 2

Preferred First-Line Agents

• Escitalopram 10 mg once daily is the top-tier choice due to minimal drug-drug interactions via CYP450 enzymes and lower risk of discontinuation syndrome compared to other SSRIs 1, 2
• Sertraline 25–50 mg once daily (titrate by 25–50 mg every 1–2 weeks to target 50–200 mg/day) is equally preferred as a first-line agent with comparable efficacy and favorable side-effect profile 1

Dosing and Titration Strategy

• Begin escitalopram at 10 mg daily; if inadequate response after one week in adults, increase to 20 mg daily 2
• Start sertraline at 25–50 mg daily to minimize initial anxiety/agitation, then increase by 25–50 mg increments every 1–2 weeks as tolerated 1
• Allow adequate trial duration: statistically significant improvement begins by week 2, clinically meaningful improvement by week 6, and maximal benefit by week 12 or later 1, 3

Alternative First-Line SNRI Options

• Venlafaxine extended-release 75–225 mg/day is an effective alternative when SSRIs fail or are not tolerated, but requires blood pressure monitoring due to risk of sustained hypertension 1, 3
• Duloxetine 60–120 mg/day provides additional benefit for patients with comorbid pain conditions 1

Second-Tier SSRIs (Reserve for Later)

• Paroxetine (20–60 mg/day) and fluvoxamine are equally effective but carry higher discontinuation-symptom rates and greater drug-interaction potential, so reserve them for when escitalopram or sertraline fail 1

Critical Monitoring Points

• Assess response using standardized scales (GAD-7 or HAM-A) monthly until symptoms stabilize, then every 3 months 1
• Monitor for common side effects: nausea (most frequent cause of discontinuation), sexual dysfunction, headache, insomnia, which typically emerge within the first few weeks and resolve with continued treatment 1
• Close monitoring for suicidal thinking is essential, especially in the first months and after dose adjustments, with pooled absolute risk of 1% versus 0.2% for placebo 1

When to Switch Medications

• If inadequate response after 8–12 weeks at therapeutic doses with good adherence, switch to a different SSRI or SNRI rather than abandoning the class 1, 3
• Approximately 25% of patients achieve remission after switching from one SSRI to another 1

Combination with Psychotherapy

• Combining an SSRI with individual cognitive-behavioral therapy (12–20 sessions) provides superior outcomes compared to either treatment alone, with moderate-to-high strength evidence 1, 4
• Individual CBT is more clinically effective and cost-effective than group therapy 1

Medications to Avoid

• Benzodiazepines should be reserved for short-term use only (days to a few weeks) due to risks of dependence, tolerance, cognitive impairment, and withdrawal; they are not appropriate as first-line or long-term therapy 1, 5
• Tricyclic antidepressants should be avoided due to unfavorable risk-benefit profile, particularly cardiac toxicity 1
• Beta-blockers (atenolol, propranolol) are deprecated by Canadian guidelines for anxiety disorders based on negative evidence 1

Maintenance Treatment Duration

• Continue effective medication for a minimum of 9–12 months after achieving remission to prevent relapse 1, 3
• For recurrent episodes, consider long-term or indefinite maintenance therapy 1

Common Pitfalls to Avoid

• Do not abandon treatment prematurely—full response may take 12+ weeks, and early response by week 4 predicts favorable 12-week outcome 1
• Do not escalate doses too quickly; allow 1–2 weeks between increases to assess tolerability and avoid overshooting the therapeutic window 1
• Do not use gabapentin or pregabalin as first-line monotherapy when evidence-based SSRIs/SNRIs are available; reserve these only for patients who fail multiple SSRI/SNRI trials or have comorbid pain conditions 6